Thus, in AML, dual/tandem CAR approaches targeting multiple antigens, including CD123/CLL1 (30), CD123/CD33, or CD33/CLL1/CD123 are being tested to fight tumor heterogeneity (47). Here, CD33 is linked to acute myeloid leukemia.